MX340718B - Proceso y sistema para obtener neurotoxina botulinica. - Google Patents

Proceso y sistema para obtener neurotoxina botulinica.

Info

Publication number
MX340718B
MX340718B MX2014008854A MX2014008854A MX340718B MX 340718 B MX340718 B MX 340718B MX 2014008854 A MX2014008854 A MX 2014008854A MX 2014008854 A MX2014008854 A MX 2014008854A MX 340718 B MX340718 B MX 340718B
Authority
MX
Mexico
Prior art keywords
botulinum neurotoxin
medium
neurotoxin
fermentation medium
botulinum
Prior art date
Application number
MX2014008854A
Other languages
English (en)
Inventor
L Ton Jennifer
A Patel Hemant
C Bates Ronald
M Ahmad Wajdie
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340718(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX340718B publication Critical patent/MX340718B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un sistema cromatográfico sustancialmente libre de producto animal (APF) para obtener una neurotoxina botulínica biológicamente activa, caracterizada porque comprende: un primer aparato para cultivar la bacteria Clostridium botulinum, el primer aparato es capaz de contener un medio de cultivo sustancialmente APF; un segundo aparato para fermentar bacteria Clostridium botulinum, la cual ha sido cultivada en el primer aparato, el segundo aparato es capaz de contener un medio de fermentación sustancialmente APF; un tercer aparato para recolectar el medio de fermentación; un cuarto aparato para concentrar el medio de fermentación cosechado y diluir el medio de fermentación filtrado; un quinto aparato para llevar a cabo una primera purificación de la neurotoxina botulínica del medio cosechado en donde el quinto aparato comprende un medio de cromatografía de intercambio aniónico, por lo que se obtiene una primera neurotoxina botulínica purificada; y un sexto aparato para llevar a cabo una segundo purificación dela primera neurotoxina botulínica purificada en donde el sexto aparato comprende un medio de cromatografía de intercambio catiónico por lo que se obtiene una segunda neurotoxina botulínica purificada, en donde la neurotoxina boltulínica obtenida tiene una potencia de por lo menos aproximadamente 2.0 veces 107 unidades/mg de la neurotoxina botulínica, la neurotoxina botulínica obtenida comprende 1 ng o menos de 1 ng de ácido nucleico residual por cada mg de neurotoxina botulínica obtenida y el proceso se lleva a cabo en una semana o menos.
MX2014008854A 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica. MX340718B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/502,181 US8129139B2 (en) 2009-07-13 2009-07-13 Process for obtaining botulinum neurotoxin
PCT/US2010/041745 WO2011008713A1 (en) 2009-07-13 2010-07-12 Process and system for obtaining botulinum neurotoxin

Publications (1)

Publication Number Publication Date
MX340718B true MX340718B (es) 2016-07-22

Family

ID=42537891

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2016009206A MX375629B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulínica.
MX2012000615A MX2012000615A (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.
MX2014008854A MX340718B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.
MX2020009978A MX2020009978A (es) 2009-07-13 2012-01-12 Proceso y sistema para obtener neurotoxina botulinica.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016009206A MX375629B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulínica.
MX2012000615A MX2012000615A (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009978A MX2020009978A (es) 2009-07-13 2012-01-12 Proceso y sistema para obtener neurotoxina botulinica.

Country Status (18)

Country Link
US (19) US8129139B2 (es)
EP (6) EP3252070B1 (es)
JP (6) JP5887268B2 (es)
KR (5) KR101784532B1 (es)
CN (2) CN106117325B (es)
BR (1) BR112012000784A2 (es)
CA (1) CA2767760C (es)
CY (2) CY1119519T1 (es)
DK (2) DK3252070T3 (es)
ES (2) ES2770031T3 (es)
HU (2) HUE047362T2 (es)
IN (1) IN2012DN00456A (es)
MX (4) MX375629B (es)
PL (2) PL2454275T3 (es)
PT (2) PT2454275T (es)
RU (1) RU2561459C2 (es)
SI (2) SI3252070T1 (es)
WO (1) WO2011008713A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
WO2006096163A1 (en) 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
PH12012500549A1 (en) 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
KR20110046178A (ko) * 2009-10-28 2011-05-04 엘지전자 주식회사 이동 단말기
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
US9605887B2 (en) 2011-07-29 2017-03-28 Hdt Expeditionary Systems, Inc. Transportable packaged ice supply system for high temperature environments
GB201113544D0 (en) * 2011-08-05 2011-09-21 Fujifilm Diosynth Biotechnologies Uk Ltd Purification process
WO2014197837A1 (en) * 2013-06-06 2014-12-11 University Of Florida Research Foundation, Inc. Materials and methods for producing a biological toxin
KR102272580B1 (ko) * 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
AU2014350370B2 (en) * 2013-11-15 2017-04-13 Novartis Ag Removal of residual cell culture impurities
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR101729251B1 (ko) 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
WO2017161345A1 (en) 2016-03-18 2017-09-21 Biomadison, Inc. Improved cell based assay
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
JP7604222B2 (ja) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
CA3060669A1 (en) * 2017-04-28 2018-11-01 Bonti, Inc. Botulinum neurotoxins production methods
EP3644971A4 (en) * 2017-06-26 2021-03-31 Bonti, Inc. CLOSTRIDIAL NEUROTOXIN FORMULATIONS AND USE
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
US11926853B2 (en) 2018-12-21 2024-03-12 The Research Foundation For Microbial Diseases Of Osaka University Botulinum toxin producing method
KR102209159B1 (ko) * 2019-03-29 2021-01-29 (주)제테마 독소의 제조방법
KR102197224B1 (ko) 2019-03-29 2020-12-31 (주)제테마 배지 조성물
KR102516204B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 정제방법
KR102447441B1 (ko) 2019-04-15 2022-09-27 (주)제테마 보툴리눔 독소의 정제방법
US10851363B1 (en) 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (ko) * 2019-08-14 2021-08-09 주식회사 프로톡스 보툴리눔 독소의 제조방법
TWI854077B (zh) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
TW202136286A (zh) 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 純化肉毒桿菌毒素的方法
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
KR102724651B1 (ko) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
KR102850152B1 (ko) * 2022-07-27 2025-08-25 (주)이니바이오 감압건조장치 및 이를 이용한 감압건조방법
US20250295741A1 (en) 2022-11-07 2025-09-25 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
CH720447A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a
WO2025111258A1 (en) * 2023-11-20 2025-05-30 Abbvie Inc. Clostridium botulinum neurotoxin serotype a compositions and improved filtration processes
DE102025101336A1 (de) 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
TW257792B (es) * 1992-10-01 1995-09-21 Lilly Co Eli
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
WO1996005222A1 (en) 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
DE69627963T2 (de) 1995-06-06 2004-03-04 Pearce, L. Bruce, Cambridge Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
ATE372376T1 (de) 1997-05-28 2007-09-15 Novartis Vaccines & Diagnostic Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
JP4055248B2 (ja) * 1998-05-25 2008-03-05 味の素株式会社 精製ヒトアクチビン及びその製造方法
GB9902000D0 (en) * 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6558926B1 (en) 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
AU1571801A (en) 1999-11-12 2001-05-30 Eli Lilly And Company Improved fermentation process
AU1486801A (en) 1999-11-15 2001-05-30 Curagen Corporation Novel growth factor polypeptides and nucleic acids encoding same
DE10004024A1 (de) 2000-01-31 2001-08-02 Guenther Bebenroth Schaltungsanordnung zum Betreiben von Leuchtdioden
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
ATE519494T1 (de) 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
WO2001058742A2 (en) 2000-02-10 2001-08-16 Magna Intertional Inc. Vehicle tailgate with storage capacity
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
ATE393780T1 (de) * 2001-08-14 2008-05-15 Statens Seruminstitut Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
KR20030060150A (ko) 2002-01-07 2003-07-16 (주)메디톡스 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
DE602004005628T2 (de) * 2003-07-02 2008-02-14 Filtertek, Inc., Hebron Halterung mit mehreren Brücken
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US20070264373A1 (en) 2004-01-26 2007-11-15 Ian Carroll Toxin Induced Sympathectomy
CA2558758C (en) 2004-02-24 2015-06-23 Allergan, Inc. Botulinum toxin screening assays
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
US20060069562A1 (en) 2004-09-10 2006-03-30 Adams Marilyn J Word categories
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US20070258992A1 (en) 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
US20070277577A1 (en) 2004-10-29 2007-12-06 Allen Clyde G Sheet metal brake and hinge mechanism therefor
ES2395544T3 (es) * 2004-12-23 2013-02-13 Novo Nordisk Health Care Ag Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés
WO2006096163A1 (en) 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
DE602006014812D1 (de) 2005-04-05 2010-07-22 Allergan Inc Lostridientoxinaktivität
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
ES2770033T3 (es) 2009-03-13 2020-06-30 Allergan Inc Ensayos de actividad de endopeptidasa redirigida basados en inmunología
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
PH12012500549A1 (en) 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
NL2010545C2 (en) 2013-03-28 2014-09-30 Ihc Holland Ie Bv Skidding system for an offshore installation or vessel.
KR101339349B1 (ko) 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9889608B2 (en) 2014-11-10 2018-02-13 International Business Machines Corporation Matching the scale of independent objects or intelligently scaling objects when 3D printing
KR101723167B1 (ko) 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101775682B1 (ko) 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법

Also Published As

Publication number Publication date
US20220033796A1 (en) 2022-02-03
KR20120105417A (ko) 2012-09-25
CN102482332B (zh) 2016-08-03
MX2012000615A (es) 2012-03-26
US20220228136A1 (en) 2022-07-21
KR20190111161A (ko) 2019-10-01
HK1247629A1 (en) 2018-09-28
AU2010273601A1 (en) 2012-02-02
CA2767760C (en) 2018-12-04
JP2017070291A (ja) 2017-04-13
KR20180122039A (ko) 2018-11-09
DK3252070T3 (da) 2020-01-20
SI3252070T1 (sl) 2020-03-31
JP6356651B2 (ja) 2018-07-11
KR20150085140A (ko) 2015-07-22
CN106117325A (zh) 2016-11-16
US8357541B2 (en) 2013-01-22
IN2012DN00456A (es) 2015-05-15
JP2016028601A (ja) 2016-03-03
JP2012532932A (ja) 2012-12-20
EP3252070B1 (en) 2019-10-02
PL3252070T3 (pl) 2020-04-30
US20210292727A1 (en) 2021-09-23
EP3252070A1 (en) 2017-12-06
RU2012104778A (ru) 2013-08-20
US20170327811A1 (en) 2017-11-16
US20220298496A1 (en) 2022-09-22
KR101784532B1 (ko) 2017-10-11
PT2454275T (pt) 2017-10-23
DK2454275T3 (en) 2017-10-23
US11525130B2 (en) 2022-12-13
ES2643554T3 (es) 2017-11-23
US11203748B2 (en) 2021-12-21
US20230021648A1 (en) 2023-01-26
JP2021193103A (ja) 2021-12-23
US20120108792A1 (en) 2012-05-03
US20220251532A1 (en) 2022-08-11
HUE047362T2 (hu) 2020-04-28
US20150184141A1 (en) 2015-07-02
US20120156756A1 (en) 2012-06-21
JP6704329B2 (ja) 2020-06-03
JP5887268B2 (ja) 2016-03-16
CN102482332A (zh) 2012-05-30
US20220145279A1 (en) 2022-05-12
WO2011008713A1 (en) 2011-01-20
US8129139B2 (en) 2012-03-06
BR112012000784A2 (pt) 2020-08-11
KR102344985B1 (ko) 2021-12-31
EP4299070A3 (en) 2024-03-27
RU2561459C2 (ru) 2015-08-27
JP2020078306A (ja) 2020-05-28
US20160097045A1 (en) 2016-04-07
US10465178B2 (en) 2019-11-05
US20110008843A1 (en) 2011-01-13
US20230029327A1 (en) 2023-01-26
US9206409B2 (en) 2015-12-08
US20120245324A1 (en) 2012-09-27
MX375629B (es) 2025-03-06
SI2454275T1 (sl) 2017-12-29
US20200071686A1 (en) 2020-03-05
JP2024111147A (ja) 2024-08-16
US11530400B2 (en) 2022-12-20
CA2767760A1 (en) 2011-01-20
CY1119519T1 (el) 2018-03-07
US11518986B2 (en) 2022-12-06
KR20170019489A (ko) 2017-02-21
US20220204958A1 (en) 2022-06-30
KR101916139B1 (ko) 2018-11-08
EP2454275A1 (en) 2012-05-23
US12241098B2 (en) 2025-03-04
US9719076B2 (en) 2017-08-01
EP4141024A1 (en) 2023-03-01
EP2454275B1 (en) 2017-07-12
CN106117325B (zh) 2021-08-10
EP4299070A2 (en) 2024-01-03
KR101667174B1 (ko) 2016-10-17
MX2020009978A (es) 2020-10-12
US8932827B2 (en) 2015-01-13
EP4699614A2 (en) 2026-02-25
CY1122567T1 (el) 2021-01-27
US11326155B2 (en) 2022-05-10
US20230123158A1 (en) 2023-04-20
PL2454275T3 (pl) 2017-12-29
EP3640259A1 (en) 2020-04-22
US8324349B2 (en) 2012-12-04
US8927229B2 (en) 2015-01-06
PT3252070T (pt) 2020-01-14
US11124786B2 (en) 2021-09-21
HUE033888T2 (en) 2018-01-29
ES2770031T3 (es) 2020-06-30
US20120123095A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
MX340718B (es) Proceso y sistema para obtener neurotoxina botulinica.
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
JP2013508388A5 (es)
SG157346A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
JP2012532932A5 (es)
BR112013028369A2 (pt) processo para a produção de isomaltulose a partir de sumos de plantas
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
Cregut et al. New insights in agar biorefinery with arylsulphatase activities
CN103525879B (zh) 一种发酵过程中添加过氧化氢生产γ-聚谷氨酸的方法
DK1268399T3 (da) Fremgangsmåde til separering af en basisk aminosyre fra fermenteringsvæske
CA2906593A1 (en) Method of protein purification
Curiel et al. Hydrolysis of tannic acid catalyzed by immobilized− stabilized derivatives of tannase from Lactobacillus plantarum
CN114341167A (zh) 纯化肉毒杆菌毒素的方法
EA201500185A1 (ru) Композиция, содержащая нуклеиновые кислоты паразитических, патогенных или инвазивных биологических систем для ингибирования и/или контроля роста указанных систем, и способ ее получения
WO2016168871A3 (de) Verfahren zur gewinnung, insbesondere zum ernten, von algen und mikroorganismen
CN106518700A (zh) 一种谷氨酸膜法生产工艺
CN112725390A (zh) 一种合成2s,3r-对甲砜基苯丝氨酸的方法
US20110201054A1 (en) Process for improved recovery of fermentation products from intracellular and extracellular presence
CN102433290B (zh) 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法
TW200716758A (en) Process for the recovery and purification of organic acids
JP5001016B2 (ja) エルロースの製造方法
MD3781G2 (ro) Procedeu de obţinere a preparatului antioxidant termostabil din biomasa cianobacteriei Spirulina platensis
US20250043230A1 (en) Selective separation of ammonium and lactate from cell culture media
Zhang et al. Efficient conversion from polysialogangliosides to monosialotetrahexosylganglioside using Oerskovia xanthineolytica YZ-2
CL2025001702A1 (es) Lavado con arginina en la purificación de proteínas.